AQUEOUS PHARMACEUTICAL COMPOSITION OF LEVILIMAB AND THE USE THEREOF Russian patent published in 2021 - IPC A61K39/395 A61K47/12 A61K47/58 A61K47/18 A61P19/02 A61P11/00 

FIELD: medicine.

SUBSTANCE: set of inventions relates to the treatment of IL-6R-associated diseases. The aqueous pharmaceutical composition of levilimab contains 5-220 mg/ml levilimab; 0.4-1.8 mg/ml sodium acetate trihydrate; 20-50 mg/ml polyol; 5-10 mg/ml glycine; and acetic acid up to pH 4.5-6.5. Disclosed are also other variants of the aqueous pharmaceutical composition of levilimab and the use thereof for the treatment or prophylaxis of an IL6R-associated disease or disorder, in particular for the treatment of rheumatoid arthritis and active rheumatoid arthritis, acute respiratory distress syndrome or cytokine release syndrome.

EFFECT: set of inventions provides stable aqueous compositions for antibodies to IL-6R of levilimab.

64 cl, 13 tbl, 6 ex, 16 dwg